Welcome to our dedicated page for Century Therapeutics SEC filings (Ticker: IPSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Century Therapeutics’ SEC filings rarely read like simple financial statements. Each 10-K weaves stem-cell science, Allo-Evasion™ gene edits and cash-burn projections into 200+ pages, leaving investors hunting for clear answers. Stock Titan fixes that problem.
Our AI-powered reader turns every Century Therapeutics SEC filing into plain-English insights. Want the latest “Century Therapeutics quarterly earnings report 10-Q filing” summarized before the market opens? We tag key figures—R&D spend, clinical trial milestones, liquidity runway—and deliver context in seconds. Need “Century Therapeutics insider trading Form 4 transactions” alerts? Real-time feeds flag executive stock moves, so you can follow “Century Therapeutics executive stock transactions Form 4” without refreshing EDGAR.
You’ll find every document, from the “Century Therapeutics annual report 10-K simplified” to “Century Therapeutics 8-K material events explained,” all indexed the moment they hit the SEC. Our platform connects forms to what matters for this particular biotech:
- 10-K: Pipeline status, manufacturing capacity and Allo-Evasion™ IP disclosures
- 10-Q: Quarterly cash burn and trial read-outs
- 8-K: Partnership deals, FDA designations and clinical setbacks
- DEF 14A proxy: “Century Therapeutics proxy statement executive compensation” showing R&D incentive structures
- Form 4: “Century Therapeutics Form 4 insider transactions real-time” for sentiment signals before data drops
Stop scrolling through dense PDFs. Stock Titan’s expert analysis, natural-language summaries and adjustable redline comparisons let you understand “Century Therapeutics SEC filings explained simply” and act on them faster.
Century Therapeutics, Inc. reported an insider transaction by a director who also serves as President and CEO. On 12/12/2025, this person acquired 52,000 shares of common stock in a transaction coded “P” at a weighted average price of $0.5837 per share.
After this purchase, the insider beneficially owns 3,322,990 common shares with direct ownership. The filing notes that the shares were bought in multiple trades between $0.577 and $0.5838 per share, and that all profits from the reported transactions will be disgorged to the company under applicable requirements.
Century Therapeutics, Inc.'s president and CEO, who is also a director, reported an automatic share withholding related to equity compensation. On 12/10/2025, 463 shares of common stock were withheld at $0.526 per share to cover tax obligations triggered by the vesting of restricted stock units. After this transaction, the executive directly owns 3,270,990 shares of Century Therapeutics common stock.
Century Therapeutics, Inc. disclosed that one of its directors submitted an initial insider ownership statement indicating no beneficial ownership of company securities. The report shows no direct or indirect holdings of common stock or derivative securities, so the director reported zero beneficial ownership as of the event date of 12/09/2025.
Century Therapeutics (IPSC) Chief Scientific Officer reported an automatic sale of company stock related to tax withholding. On 11/20/2025, the reporting person sold 5,462 shares of common stock at $0.501 per share in a transaction labeled as a sale to cover tax obligations from vesting restricted stock units. After this transaction, the reporting person beneficially owned 987,027 shares directly and 10,697 shares indirectly through a trust. The filing notes that the trust-held shares are disclaimed as beneficially owned except to the extent of any pecuniary interest.
Century Therapeutics, Inc. (IPSC) is calling a virtual 2026 Special Meeting of Stockholders on January 22, 2026 to vote on two key proposals. The first would amend its certificate of incorporation to allow the board, any time before June 30, 2026, to implement a reverse stock split of the company’s common stock at a ratio between 1‑for‑5 and 1‑for‑30, at the board’s discretion. A reverse split would reduce the number of shares outstanding but keep authorized shares the same, materially increasing authorized but unissued shares and proportionally adjusting outstanding options, RSUs, warrants and plan reserves.
The board states the main goal is to help IPSC regain and maintain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a deficiency notice and transfer to the Nasdaq Capital Market, and to broaden potential investor interest. The filing explains risks, including possible reduced liquidity, more odd-lot holdings, no guarantee of a sustained higher share price, and an increased pool of authorized but unissued shares that could affect future capital raising and control dynamics. The second proposal would permit adjournment of the meeting if more time is needed to secure enough votes or a quorum.
Century Therapeutics, Inc. (IPSC) President and CEO insider purchase was reported on a Form 4. The reporting person, who is also a director, bought 35,000 shares of Century Therapeutics common stock on 11/19/2025 at a weighted average price of $0.4951 per share. Following this open-market purchase, the insider beneficially owns 3,271,453 shares, held directly. The filing notes that all profits from the reported transactions will be disgorged to the issuer pursuant to applicable requirements, and the price reflects multiple trades between $0.488 and $0.5005 per share.
Century Therapeutics, Inc. (IPSC) reported an insider transaction by its President and CEO, who is also a director of the company. On 11/17/2025, the reporting person sold 32,456 shares of common stock at a price of $0.454 per share.
According to the explanation provided, these sales represent shares sold to cover tax withholding obligations arising from the vesting of restricted stock units and were described as automatic, not at the discretion of the reporting person. After this transaction, the reporting person beneficially owned 3,236,453 shares of Century Therapeutics common stock, held directly.
Century Therapeutics, Inc. (IPSC) furnished materials related to its latest quarter and pipeline. The company provided an earnings press release for the quarter ended September 30, 2025, and an updated investor presentation. It also announced its first Type 1 diabetes program, CNTY-813.
The earnings release (Exhibit 99.1), investor presentation (Exhibit 99.2), and CNTY-813 press release (Exhibit 99.3) were furnished on November 13, 2025 and are not deemed “filed” under the Exchange Act.
Century Therapeutics (IPSC) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $34,422$9,591, driven by $109,164 of collaboration revenue recognized in Q1 when option rights expired.
Total assets were $244,717 versus $353,216 at year‑end, reflecting lower investments and lease assets. Cash, cash equivalents and investments were $132,748 as of September 30, 2025. Current liabilities declined to $22,026 from $129,782, primarily as deferred revenue was recognized. Stockholders’ equity rose to $176,348.
Q3 operating expenses were $36,124, including R&D $22,526, G&A $6,835, and a $6,763 impairment tied to lease strategy changes. The company executed lease modifications, recording a $1,395 gain and expects Seattle and Boston lease terminations by early 2026 with a new Watertown lease to commence thereafter. Management states it has adequate resources to operate for at least the next 12 months. As of November 1, 2025, common shares outstanding were 87,307,091.
Century Therapeutics (IPSC) insider transaction: The company’s SVP Finance & Operations reported selling 292 shares of common stock at $0.586 on November 3, 2025.
The filing states these sales were executed to satisfy tax withholding obligations tied to the vesting of restricted stock units and were automatic, not at the reporting person’s discretion. Following the transaction, the insider beneficially owns 405,131 shares, held directly.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
